Stroke, Vol 21, 602-605, Copyright © 1990 by American Heart Association
DA Phillips, M Fisher, MA Davis, TW Smith and RH Pang
Fibrinolytic therapy may be effective in the treatment of ischemic stroke,
and clinical trials are under way. We evaluated two fibrinolytic agents, an
analogue of tissue plasminogen activator (Fb-Fb- CF, the catalytic fragment
of the tissue plasminogen activator molecule with a prolonged serum
half-life, n = 10) and streptokinase (n = 7), in a rabbit model of embolic
stroke. Both agents were given 3 hours after stroke onset, a time relevant
to the clinical setting. Fb-Fb-CF was significantly better (p less than
0.04) than saline (n = 7) in restoring blood flow to previously occluded
intracranial arteries, but streptokinase was ineffective. Neither
fibrinolytic agent was associated with a substantial risk for intracerebral
hemorrhagic side effects. Our study demonstrates that Fb-Fb-CF can safely
and effectively reperfuse rabbit intracranial arteries 3 hours after
occlusion, while streptokinase does not.
ARTICLES
Delayed treatment with a t-PA analogue and streptokinase in a rabbit embolic stroke model
Department of Radiology, University of Massachusetts Medical School, Worcester.
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1990 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |